Global Law Firm Greenberg Traurig, LLP expands its global Intellectual Property (IP) & Technology capabilities with the addition of Jayadeep “Jay” R. Deshmukh as a shareholder in the New York office. He joins from Kasowitz Benson Torres and previously served as senior vice president of Global IP at Ranbaxy Laboratories, an international pharmaceutical company.

Deshmukh brings over 20 years of experience representing major pharmaceutical and biotech companies in complex IP and patent litigation, focusing on both Hatch-Waxman Act litigation and the growing area of biologic and biosimiliar patents. Some of his notable litigation cases include representing a major cholesterol lowering generic and a biosimiliar of a leading biologic treatment for rheumatoid arthritis and Crohn’s disease.

Deshmukh also regularly serves as settlement and Food and Drug Administration (FDA) counsel for smaller pharmaceutical companies, advising on exclusivity matters against the Office of the Chief Counsel of the FDA.

“Jay’s experience will complement our already expansive life sciences and IP capabilities as we strategically further Greenberg Traurig’s market dominance in these areas in response to our growing roster of clients who need sophisticated counsel on the evolving regulations in the industry. In addition, the firm’s unique, far-reaching, and unified global platform, with offices in cities and countries on the cutting edge of research and technology, allows us to work seamlessly around the world, offering the best value and service to clients,” Richard A. Rosenbaum, Executive Chairman of Greenberg Traurig said.

The biotech industry is increasingly playing a critical role in medicine, offering both revolutionary therapies and the treatment of formerly untreatable conditions. In addition, the Affordable Care Act’s Biologics Price Competition and Innovation Act provides a faster pathway to market for biosimilars – versions of biologics that mimic the originals – ensuring patients easier access and more affordable treatments. As a result, there are now multiple biosimilars of each biologic competing for approval. The evolving landscape requires attorneys with Deshmukh’s specific knowledge to guide clients through the patent process.

“Greenberg Traurig is known around the world for its leading pharmaceutical and biotechnology capabilities and we are thrilled to add someone with Jay’s deep experience in Hatch-Waxman and biosimiliar patent litigation to our team,” said Scott J. Bornstein, co-managing shareholder of Greenberg Traurig’s New York office and co-chair of the firm’s global IP & Technology Practice.

“I am excited to join Greenberg Traurig and collaborate with top tier professionals across the globe in locations at the forefront of biologic development such as New York, New Jersey, Boston, Washington, D.C., California, and Tel Aviv. With the firm’s collaborative global culture, I can work efficaciously with a biotech company that developed a drug in one country and the manufacturer of that drug in another country. I know the possibilities to grow my practice and benefit my clients are limitless here,” Deshmukh said.

Other recent Greenberg Traurig hires in life sciences and IP include Prashant Girinath and David S. Harburger in Boston, Jeffrey C. Giering in Orange County, David A. Gay and Michael L. Hebert in Los Angeles, and Charles J. Andres in Washington, D.C.

Deshmukh is recognized as a leading patent litigator by The Legal 500 and LMG Life Sciences. He received his J.D. from Case Western Reserve University School of Law, his M.S. from Cleveland State University, and his B.E. from Manipal Institute of Technology.